Actinium Pharmaceuticals, Inc. (ATNM)
| Market Cap | 46.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.04M |
| Shares Out | 31.20M |
| EPS (ttm) | -1.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 193,901 |
| Open | 1.540 |
| Previous Close | 1.530 |
| Day's Range | 1.440 - 1.554 |
| 52-Week Range | 1.029 - 2.410 |
| Beta | -0.25 |
| Analysts | Strong Buy |
| Price Target | 4.50 (+204.05%) |
| Earnings Date | Nov 13, 2025 |
About ATNM
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ATNM stock is "Strong Buy." The 12-month stock price target is $4.5, which is an increase of 204.05% from the latest price.
News
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC DATROWAY®) an...
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology withcontinued expression following androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy, enabling po...
Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
ATNM-400 is advancing as a first-in-class, multi-tumor Actinium-225 radiotherapy candidate with activity across prostate and lung cancers, two of the largest cancer indications globally New preclinica...
Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
- ATNM-400 targets a highly differentiated, non-PSMA antigen associated with the development and progression of prostate cancer, exhibiting potent therapeutic activity independent of PSMA expression...
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit
- ATNM-400 demonstrates robust efficacy in prostate cancer tumor models with acquired resistance to Pluvicto ® and enzalutamide, follow-up continues - ATNM-400 significantly improved survival ...
Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination - ATNM-...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM
NEW YORK , May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during ...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM).
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
- Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy - Iom...
Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation
SAN DIEGO , April 30, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Investors w...
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
- Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists follo...
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML...
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
NEW YORK, NY / ACCESS Newswire / April 19, 2025 / Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Conta...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM
NEW YORK , April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM durin...
Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of ...
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in health...